Reuters logo
BRIEF-Sunovion submits new drug application for dasotraline to the FDA for the treatment of patients with ADHD
August 31, 2017 / 12:11 PM / 23 days ago

BRIEF-Sunovion submits new drug application for dasotraline to the FDA for the treatment of patients with ADHD

Aug 31 (Reuters) - Sumitomo Dainippon Pharma Co Ltd

* Sunovion submits new drug application for dasotraline to the FDA for the treatment of patients with ADHD

* ‍Sunovion Pharmaceuticals Inc - submitted NDA to U.S. FDA for dasotraline for treatment of children, adolescents and adults with ADHD​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below